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 Atrial fibrillation (AF) is one of the most commonly diagnosed cardiac arrhythmias; however, 
details regarding the risk factors of AF are not necessarily well identified.1,2 This literature review will 
investigate the likelihood of a direct correlation between pre-existing type 2 diabetes mellitus (T2DM) 
and new-onset AF. Highlighting a definitive association between AF and T2DM has been a perplexing 
pursuit in research studies of epidemiology.2 The literature review will examine multiple studies and 
investigate the extent and significance to which T2DM and AF are related. The specific goal will be to 
assess whether T2DM patients over the age of 55, with Hemoglobin A1c (HbA1c)  less than 7% and 
lifestyle and medication compliance, are less likely to be diagnosed with new onset AF within 5 years of 
becoming diabetic, than those with poor diabetic control and elevated HbA1c. HbA1c is a blood test 
used to measure the average glucose levels in the bloodstream over the past three months.  
 Understanding the relationship between pre-existing T2DM and new-onset AF could greatly 
benefit and reduce mortality in this patient population. AF is a known risk factor and a common cause of 
death due to cerebral vascular accidents (CVA).1 Reducing the occurrence of AF  among the vulnerable 
and immunocompromised T2DM patient population could have immeasurable benefits and lead to 
significant decreases in patient mortality.  This literature review will summarize several studies, 
including meta-analyses, case-control studies, and retrospective cohort studies.  
 
Does intense glycemic control in T2DM patients reduce the occurrence of new-onset AF? 
 
 The role of glycemic control in T2DM patients with new-onset AF has been at the center of many 
research studies. These studies have focused on glucose levels and HbA1c, in order to establish a 
correlation between T2DM and new-onset AF, possibly because these are known, measurable, and 
reliable prognostic indicators of diabetic control.  
 The strongest piece of evidence investigating this correlation comes from The Action to Control 
Cardiovascular Risk in Diabetes study (ACCORD study), which was published in 2014. The research study 
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included 10,082 T2DM patients. The ACCORD study investigated the impact of glycemic control and the 
incidence of new-onset AF. The study used HbA1c > 7.5% and other inclusion criteria to determine the 
study groups.  Some participants were treated with intensive glycemic control methods, while others 
were treated with standard control methods to see how glycemic control impacted new-onset AF.  The 
analysis used  a randomized double-blind study method, and a multivariate model (weight, age, heart 
rate, blood pressure and history of heart failure) was used to calculate incidence of AF. The findings 
were significant because they showed that intensive glycemic control in patients between the ages of 
55-79 did not affect the frequency of new-onset AF. In fact, slightly more people in the standard therapy 
group had new-onset AF compared to the intensive therapy group.1 
 However, it should be noted that only periodic electrocardiogram readings were obtained 
during appointed clinical site visits, and continuous event monitors, such as Holter monitors, were not 
utilized for 24-hour observation and recording.1  Because of this technique of recording results, it is 
possible that episodes of AF were missed by the research team.  Another limitation of the study is that 
no data were collected regarding inpatient admission or emergency department visits.  Most 
significantly, the ACCORD study only focused on standard vs intensive glycemic control.  
 
Does poor glycemic control in T2DM patients increase the occurrence of new-onset AF? 
 
 Unfortunately, it is very common to work with medication non-compliant T2DM patients. 
Medication compliance is a multifactorial problem, but T2DM patients who ignore their medication 
regimen and necessary lifestyle changes will likely have poor glycemic control and elevated HbA1c. 
Some research studies have found that poor glycemic control is associated with an increase in new-
onset AF. For example, studies in China that included Holter monitoring identified a link between poor 
glycemic control, elevated HbA1c, and increased prevalence in new-onset AF. Additionally, one animal 
study also linked elevated glucose levels to an increased prevalence of new-onset AF. 
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 A retrospective cohort study was conducted at the Shanghai Ninth People's Hospital of 505 
T2DM patients from 2008-2015.  The incidence of new-onset AF was investigated.  Holter monitor or 
electrocardiogram recordings were obtained from hospital records or medical examinations conducted 
on a monthly basis. Out of 505 patients, 48 developed new-onset AF. The group with the higher 
elevation and variability of HbA1c was associated with a greater increase in new-onset AF. These 
findings suggest that HbA1c variability is, in fact, a predictor of new-onset AF in patients with T2DM.3 
Additionally, increased HbA1c levels were associated with an increased risk of AF in prospective cohort 
studies but not in case-control studies.4  
 One method to further investigate glycemic control and its relation to new-onset AF is to utilize 
an animal study. A study published in 2014 by the Department of Cardiology at Otia University in Japan 
investigated whether or not glucose fluctuations aggravate cardiac fibrosis and increase the occurrence 
of AF in rats with T2DM. In this study, glucose fluctuations were found to increase the incidence of AF in 
T2DM rats.  A single IV injection of streptozotocin induced T2DM rats were randomly divided into three 
groups: uncontrolled, controlled, and T2DM rats with variable glucose fluctuations. The rats were 
administered long-acting insulin according to their group.  At the end of a twelve-week period, the rat 
hearts were excised. They evaluated the hearts for cardiac fibrosis using masson trichrome staining. The 
inducibility of new-onset AF was significantly higher in uncontrolled T2DM rats when compared to 
controlled T2DM rats. AF onset was greatest in T2DM rats with high glucose fluctuations. This study links 
rises in glucose fluctuation to the induction of cardiac fibrosis. Furthermore, this study suggests that 
increases in reactive oxygen species through increases in Txnip gene expression allow glucose 
fluctuations to lead to cardiac fibrosis, and eventually AF.5 
 
Can medication compliance keep T2DM patients from acquiring new-onset AF? 
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 Metformin is widely considered the medication of choice for the initial treatment of T2DM.  
Thus, compliance with metformin typically leads to improved glycemic control. The following research 
study examined the role of medication compliance in lowering AF risk among T2DM patients.   
 A 2014 study investigated the relevance of metformin compliance and lowering new-onset AF 
risk amongst the T2DM patient population. This study used a population-based dynamic cohort and in 
vitro design.  Information was gathered from national health care databases such as the Taiwan National 
Health & Research Institute. This large study followed 645,710 newly diagnosed T2DM patients for 11 
years. None of the patients were insulin dependent. Two study groups of oral diabetic medication 
prescribed patients were created. One group used metformin and the other used a non-metformin oral 
diabetic medication. The study findings were significant (P < 0.05) and identified a decrease in new-
onset atrial tachycardia when metformin was used as 1st line T2DM treatment. This finding was likely 
attributed to metformin’s ability to diminish atrial cell tachycardia induced oxidative stress and 
myolysis.6 Such results may raise the question, “Is new-onset AF related to not only lack of glycemic 
control but also medication noncompliance?”  
 Some patients with AF, whether T2DM or not, are resistant to initial medical treatment and 
require more invasive procedures such as catheter ablation to convert out of AF and into a normal sinus 
rhythm.  If T2DM patients are in fact at an increased risk of new-onset AF, should they be treated with 
catheter ablation early after diagnosis, or should all other treatment measures be exhausted first? 
 A 2015 systematic review examined the etiology of AF through specific molecular pathways, and 
investigated the effectiveness of treatment plans for AF in T2DM patients. The data were based on the 
findings of multiple studies pertaining to the correlation between AF and T2DM.  For example, The 
Framingham Heart Study and The ACCORD study were both utilized.  This systematic review found that 
AF in T2DM patients is a significant cause of CVA.  Furthermore, the correlation of AF and T2DM largely 
increases the likelihood of morbidity and mortality in the T2DM population.7  
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 But what about treatment modalities and their effectiveness?  This systematic review found that 
patients treated with catheter ablation had less incidence of future AF than those treated 
pharmacologically for AF.7 Unfortunately, only a small percentage had T2DM, so it is yet unknown if 
catheter ablated patients with AF and T2DM would greatly benefit from this treatment modality.  
Furthermore, the focus of this review was the prevention of AF in the setting of pre-existing T2DM.  
 
What role do lifestyle interventions and risk stratification have on new-onset AF in T2DM patients? 
 
 Management of T2DM can be properly optimized when patients take ownership of medication 
compliance, and perhaps even more importantly, lifestyle choices. Starting a balanced diet and 
implementing an exercise regimen is crucial to improving glycemic control and T2DM treatment. The 
following study examined how lifestyle intervention in T2DM patients affected the prevalence of new-
onset AF. 
 In 2015 the Look AHEAD (Action For Health in Diabtets) randomized trial investigated the effects 
of intensive lifestyle intervention in T2DM patients over a nine-year period. The goal was to see if there 
was any change in risk of acquiring new-onset AF.  The study used 5,067 obese or overweight people 
with T2DM and no history of AF. The population was divided into two groups randomly, one with 
intensive lifestyle intervention and the other with only diabetic education and supportive care. The 
onset of AF was discovered by electrocardiogram and discharge summaries from hospitals. The findings 
suggested that among overweight and obese T2DM patients there was no reduction in the likelihood of 
new-onset AF when intensive lifestyle modifications were implemented.  In fact, results were similar in 
both groups. What remained a common factor in this study was that all patients did have T2DM. While 
lifestyle intervention is paramount in treating T2DM, according to this study, it will not significantly help 
reduce the likelihood of new-onset AF.8  
 A crucial aspect of treating AF beyond rate/rhythm control is anticoagulation. Due to the known 
increase in the risk of CVA associated with AF, anticoagulation is a cornerstone of AF management. 
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Traditionally, comorbidities and age have determined the need for anticoagulation through the 
CHA2DS2-VASc scoring system. Risk stratification techniques such as CHAD-VASC scoring may help 
greatly to see if uncontrolled T2DM is linked to increased likelihood of new-onset AF. 
 In 2017 a retrospective cohort study examined subjects enrolled in a large nationwide dataset 
that looked at T2DM patients and used the CHADS-VASC score to stratify new-onset of AF. The study 
population was identified from a longitudinal health insurance database provided by the National Health 
Research Institute, and it included 69,530 patients. Patients who had a prior diagnosis or history of AF 
before the index date were excluded from the study. A CHADS-VASC score was calculated for each group 
using the Kaplan Meier method. Findings from this study suggested the risk of AF among patients with 
T2DM and no hyperosmolar hyperglycemic state (HHS) increased with increasing CHADS-VASC scores. 
The incidence of new-onset AF increased significantly (P < 0.05) when the CHAD-VASC score increased 
from 1 to 6 or greater among patients with T2DM and HHS.9 There is clinical significance to the above 
findings because of the increasing need for anticoagulation as a CHADS-VASC score rises to prevent the 
risk of cardiovascular events such as CVA. Furthermore, the findings of this study suggest that new-onset 
AF is more common in patients with T2DM, comorbid conditions, advanced age, and a history of HHS, 
further raising suspicion that uncontrolled T2DM may be linked to increased likelihood of new-onset AF.  
Hospitalizations and rates of new-onset AF in T2DM patients. 
 As illustrated by the results of the next two studies, T2DM patients are being diagnosed with 
new-onset AF. Studies continue to produce conflicting evidence as to why T2DM patients may or may 
not be more likely to have new-onset AF. Researchers have struggled to determine the cause of new-
onset AF in T2DM. It has been challenging for researchers to determine if there are any mitigating 
factors that can reduce the likelihood of acquiring AF. At a minimum, these studies highlight the need to 
further investigate the association between existing T2DM and new-onset AF.  
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 A 2011 meta-analysis of cohort and case-control studies investigated T2DM patients with 
glucose intolerance or impaired fasting glucose and AF through computerized search parameters. The 
goal of this study was to use a meta-analysis of previously published studies to reliably determine what 
link exists between T2DM and new-onset of AF. This research study included a population of over 1-
million T2DM patients. This study found that T2DM was associated with a 10-time increase in the 
occurrence of new onset AF Individuals with T2DM have approximately a 40% increase in new onset AF 
compared to those without T2DM. The strength of this study was simple; it was very large and gathered 
data from legitimate primary sources. The study findings support the concept that T2DM patients are at 
increased risk of acquiring new-onset AF. However, the studies limitations included a lack of subtype 
evidence such as new-onset AF after excessive binge drinking.2  
 In Lombardy, Italy, a large population-based study was conducted from 2000-2010. It focused on 
T2DM as a risk factor for AF, as well as other cardiovascular diseases. This study was conducted 
retrospectively and utilized administrative health databases to acquire the entirety of its data.  While 
this study design, and others like it, may have some obvious limitations, it also has the advantage of 
easily including large numbers of patients. This study utilized 285,428 participants with T2DM and 
followed them closely to see who would acquire new-onset AF and who would not.  The findings were 
significant because they illustrated that patients with T2DM had more hospitalizations due to new-onset 
AF than those without T2DM.  In fact, T2DM was identified as having a 32% greater risk for new-onset 




 The goal of this literature review was to answer the following question: Are type T2DM patients 
over the age of 55 with medication compliance and HbA1c less than 7% less likely to be diagnosed with 
new-onset AF within 5 years of becoming diabetic than those with poor diabetic control and elevated 
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HbA1c? In this literature review, the incidence of new-onset AF was elevated among the T2DM patient 
population. These studies were unable to identify with certainty what contributing factors led to the 
association of the two conditions. Despite in-depth examination of glycemic control, HbA1c levels, 
lifestyle intervention, medication compliance, and efficacy of various treatment modalities more studies 




 There is a clear association between T2DM and AF, but to what degree remains somewhat 
unknown.  According to some glycemic control studies, well-controlled T2DM with therapeutic HbA1c 
levels offers little advantage in decreasing the likelihood of new-onset AF amongst T2DM patients.1 In 
contrast, other studies that focused on uncontrolled glycemic levels, or did not focus on glucose control 
at all signified that T2DM was, in fact, an independent risk factor for AF due to the increased number of 
new-onset hospitalizations and diagnosis. 2,3,4,10 To further understand the relationship between T2DM 
and AF, additional research is required.  In the meantime, medical providers can follow established 
principles to manage patients with T2DM, AF, or perhaps both conditions simultaneously. 
 Awareness that both T2DM and AF are associated is paramount. As a medical practitioner, it is 
important to understand that lowering HbA1c to a therapeutic level (HgbA1c < 7.0%) is the first step 
towards controlling T2DM. Being aware of T2DM guidelines and stressing the importance of medication 
compliance is part of serving the patient population to the best standard of care. Well controlled T2DM 
may not completely rule out the possibility of new-onset AF. Medical professionals should be aware that 
new-onset AF is a possibility in T2DM patients, and then survey for signs and symptoms associated with 
AF. These actions may help greatly reduce the incidence of poor cardiovascular outcomes such as CVA or 
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